The SVP, Legal and Compliance of Versartis (NASDAQ: VSAR) is Selling Shares

By Carrie Williams

Yesterday, the SVP, Legal and Compliance of Versartis (NASDAQ: VSAR), Shane Ward, sold shares of VSAR for $20.41K.

In addition to Shane Ward, 10 other VSAR executives reported Sell trades in the last month. This is Ward’s first Sell trade following 3 Buy transactions.

The company has a one year high of $16.55 and a one year low of $6.17. Currently, Versartis has an average volume of 139.5K.

Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $23.33, reflecting a -38.7% downside.

In the last 30 days, insiders have sold $180.2K worth of VSAR shares and purchased $1.39M worth of VSAR shares. The insider sentiment on Versartis has been positive according to 36 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Versartis, Inc. is an endocrine-focused biopharmaceutical company. It develops long-acting therapeutic proteins for the treatment of endocrine disorders. The company develops new therapeutic proteins utilizing the novel half-life extension technology XTEN. Versartis was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Redwood City, CA.